Mon, March 10, 2025
Sun, March 9, 2025
[ Yesterday Afternoon ] - MSN
Leaving Your Job? 5 Healthcare Options
Sat, March 8, 2025
Fri, March 7, 2025
Thu, March 6, 2025
Wed, March 5, 2025
Tue, March 4, 2025
Mon, March 3, 2025
[ Mon, Mar 03rd ] - NDTV
Yoga Poses For Indigestion
Sun, March 2, 2025
[ Sun, Mar 02nd ] - NDTV
7 Yoga Asanas For PCOD
Sat, March 1, 2025
Fri, February 28, 2025
Sun, February 23, 2025
Sat, February 22, 2025

Data on new Novo Nordisk obesity drug disappoints in trial, stirs worries Lilly gaining edge in sector


Published on 2025-03-10 09:23:37 - Reuters
  Print publication without navigation

  • Novo Nordisk on Monday revealed data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over Novo in the weight-loss drugs market.

The article discusses a recent trial of a new obesity drug from Novo Nordisk, which has shown less promising results than anticipated, causing concerns about the company's competitive edge in the obesity treatment market. The drug, aimed at reducing weight through a novel mechanism, did not meet the high expectations set by earlier trials, leading to a dip in investor confidence. Meanwhile, Eli Lilly, another major player in the pharmaceutical industry, appears to be gaining ground with its own obesity treatments, potentially positioning it to lead the sector. This development has stirred worries among stakeholders about Novo Nordisk's future market position, especially as the demand for effective weight loss solutions continues to grow.

Read the Full Reuters Article at:
[ https://www.msn.com/en-us/health/weightloss/data-on-new-novo-nordisk-obesity-drug-disappoints-in-trial-stirs-worries-lilly-gaining-edge-in-sector/ar-AA1ACcrc ]